1. 1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial. (September 2015) Authors: Gluz, O.; Nitz, U.; Kreipe, H.H.; Christgen, M.; Kates, R.E.; Hofmann, D.; Shak, S.; Clemens, M.; Kraemer, S.; Aktas, B.; Kuemmel, S.; Reimer, T.; Kusche, M.; Heyl, V.; Lorenz-Salehi, F.; Just, M.; Liedtke, C.; Wuerstlein, R.; Harbeck, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ADAPTcycle – adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk HR+/HER2- early breast cancer. (March 2019) Authors: Harbeck, N.; Gluz, O.; Christgen, M.; Graeser, M.; Hilpert, F.; Kreipe, H.H.; Nitz, U.; Kates, R.; Schinkoethe, T.; Kuemmel, S. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay. (March 2017) Authors: Mamounas, E.P.; Goldstein, L.J.; Penault-Llorca, F.; Roché, H.; Gluz, O.; Harbeck, N.; Nitz, U.; O'shaughnessy, J.; Albain, K.S. Journal: Breast Issue: Volume 32(2017)Supplement 1 Page Start: S98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Differential impact of prognostic parameters in hormone receptor-positive lobular early breast cancer in the WSG PlanB trial. (October 2020) Authors: Christgen, M.; Harbeck, N.; Gluz, O.; Raap, M.; Christgen, H.; Clemens, M.; Malter, W.; Nuding, B.; Aktas, B.; Kuemmel, S.; Reimer, T.; Stefek, A.; Krabisch, P.; Just, M.; Graeser, M.; Baehner, R.; Wuerstlein, R.; Nitz, U.; Kates, R.; Kreipe, H. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with 1-3 involved lymph nodes. (March 2017) Authors: Gluz, O.; Nitz, U.; Christgen, M.; Kates, R.; Clemens, M.; Nuding, B.; Shak, S.; Würstlein, R.; Kreipe, H.; Harbeck, N. Journal: Breast Issue: Volume 32(2017)Supplement 1 Page Start: S93 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P231 Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study. (March 2015) Authors: Gluz, O.; Nitz, U.; Christgen, M.; Kreipe, H.; Kates, R.E.; Kuemmel, S.; Braun, M.; Schumacher, C.; Wuerstlein, R.; Harbeck, N. Journal: Breast Issue: Volume 24(2015)Supplement 1 Page Start: S104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P246 Risk assessment by St.Gallen 2013 recommendation and Oncotype DX®: results from the WSG PlanB trial. (March 2015) Authors: Nitz, U.; Christgen, O. Gluz, H. Kreipe, M.; Clemens, R.E. Kates, M.; Kraemer, S.; Aktas, B.; Kuemmel, S.; Harbeck, N. Journal: Breast Issue: Volume 24(2015)Supplement 1 Page Start: S110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗